Literature DB >> 23720095

Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei.

Shigeki Kusamura1, Ionut Hutanu, Dario Baratti, Marcello Deraco.   

Abstract

BACKGROUND: Incomplete cytoreduction (IC) is one of the main prognostic factor in pseudomyxoma peritonei (PMP). We evaluated the ability of preoperative Ca125, CEA, and Ca19-9 to predict IC and prognosis in PMP.
METHODS: One hundred fifty-six cases elected candidate to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy from 1996 to 2011 were included in the study. We assessed the: (1) optimal cut-off values for circulating Tumor markers (CTM) in predicting IC (residual disease >2.5 mm) using receiver-operating characteristics (ROC); (2) discriminant power of CTM and risk prediction models for IC by calculating the area under ROC curve (AUC-ROC); (3) prognostic factors using Cox proportional-hazard model.
RESULTS: Optimal cut-offs were 125 U/ml for Ca125, 18 ng/ml for CEA, and 89 U/ml for Ca19-9. The AUCs-ROC were 0.76, 0.68, and 0.69 for Ca125, CEA, and Ca19-9, respectively. The addition of CTM to risk prediction model that considered preoperative clinicopathological factors increased marginally the AUC-ROC (0.80-0.84). Ca125 > 125 U/ml, Ca19-9 > 89 U/ml independently affected overall survival.
CONCLUSIONS: Preoperative CTMs were reasonable but not perfect discriminators of IC. Moreover, Ca125 and Ca19-9, using new cut-off values, were proven to be new strong prognostic factors that overcome the value of disease extension and histological subtype.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23720095     DOI: 10.1002/jso.23329

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Selection Criteria for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Special Emphasis on Laparoscopy as an Efficient Tool.

Authors:  Miklos Acs; Aydin Dadras; Sebastian Blaj; Hubert Leebmann; Pompiliu Piso
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 2.  Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.

Authors:  Megan M Harper; Joseph Kim; Prakash K Pandalai
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

3.  Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei.

Authors:  Lei Liang; Jingyang Fang; Xuedi Han; Xichao Zhai; Yan Song; Yiyan Lu; Qian Zhang; Ruiqing Ma
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

4.  Radiomics analysis based on CT's greater omental caking for predicting pathological grading of pseudomyxoma peritonei.

Authors:  Nan Zhou; Ruixue Dou; Xichao Zhai; Jingyang Fang; Jiajun Wang; Ruiqing Ma; Jingxu Xu; Bin Cui; Lei Liang
Journal:  Sci Rep       Date:  2022-03-15       Impact factor: 4.379

Review 5.  Comprehensive Understanding and Evolutional Therapeutic Schemes for Pseudomyxoma Peritonei: A Literature Review.

Authors:  Suiting Ye; Song Zheng
Journal:  Am J Clin Oncol       Date:  2022-04-14       Impact factor: 2.787

6.  Pseudomyxoma peritonei: a clinical case of this poorly understood condition.

Authors:  Ana Maria de Oliveira; Catarina Graça Rodrigues; Alexys Borges; Alexandra Martins; Sofia Loureiro Dos Santos; Francisco Rocha Pires; João Mascarenhas Araújo; João Ramos de Deus
Journal:  Int J Gen Med       Date:  2014-03-03

Review 7.  Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; David Lawson Morris
Journal:  Orphanet J Rare Dis       Date:  2014-05-05       Impact factor: 4.123

8.  Improved Outcome Prediction for Appendiceal Pseudomyxoma Peritonei by Integration of Cancer Cell and Stromal Transcriptional Profiles.

Authors:  Claudio Isella; Marco Vaira; Manuela Robella; Sara Erika Bellomo; Gabriele Picco; Alice Borsano; Andrea Mignone; Consalvo Petti; Roberta Porporato; Alexandra Ambra Ulla; Alberto Pisacane; Anna Sapino; Michele De Simone; Enzo Medico
Journal:  Cancers (Basel)       Date:  2020-06-08       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.